Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2900)
All Articles published online
|
Apr 28, 2005 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Fan YZ, Fu JY, Zhao ZM, Chen CQ. Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. World J Gastroenterol 2005; 11(16): 2431-2437 [PMID: 15832413 DOI: 10.3748/wjg.v11.i16.2431] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i16/2431.htm |
| Number | Citing Articles |
| 1 |
Ming-Che Chang, En-Tung Tsai, Jin-Yi Wu, Hui-Fen Liao, Yu-Jen Chen, Cheng-Deng Kuo. N-Farnesyloxy-norcantharimide and N-farnesyl-norcantharimide inhibit the progression of leukemia and increase survival days in a syngeneic mouse leukemia model. Anti-Cancer Drugs 2015; 26(5): 508 doi: 10.1097/CAD.0000000000000210
|
| 2 |
Yulin Ren, A. Douglas Kinghorn. Antitumor potential of the protein phosphatase inhibitor, cantharidin, and selected derivatives. Bioorganic & Medicinal Chemistry 2021; 32: 116012 doi: 10.1016/j.bmc.2021.116012
|
| 3 |
You-Ming Jiang, Zhen-Zhi Meng, Guang-Xin Yue, Jia-Xu Chen. Norcantharidin Induces HL-60 Cells Apoptosis In Vitro. Evidence-Based Complementary and Alternative Medicine 2012; 2012: 1 doi: 10.1155/2012/154271
|
| 4 |
Yu-Jen Chen, Wei-Min Chang, Yi-Wen Liu, Chia-Yun Lee, Yi-Hua Jang, Cheng-Deng Kuo, Hui-Fen Liao. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chemico-Biological Interactions 2009; 181(3): 440 doi: 10.1016/j.cbi.2009.07.004
|
| 5 |
Jie Tao, Xin-Sen Xu, Yan-Zhou Song, Kai Qu, Qi-Fei Wu, Rui-Tao Wang, Fan-Di Meng, Ji-Chao Wei, Shun-Bin Dong, Yue-Lang Zhang, Min-Hui Tai, Ya-Feng Dong, Lin Wang, Chang Liu. Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescence. World Journal of Gastroenterology 2014; 20(28): 9497-9505 doi: 10.3748/wjg.v20.i28.9497
|
| 6 |
Chen-Hsi Hsieh, K. S. Clifford Chao, Hui-Fen Liao, Yu-Jen Chen. Norcantharidin, Derivative of Cantharidin, for Cancer Stem Cells. Evidence-Based Complementary and Alternative Medicine 2013; 2013: 1 doi: 10.1155/2013/838651
|
| 7 |
Song Tao Xu, Qi Cheng, Shu Mei Rao. The Effect of Norcantharidin on Proliferation and Invasiveness of SW579 Cell. Advanced Materials Research 2014; 1058: 335 doi: 10.4028/www.scientific.net/AMR.1058.335
|
| 8 |
Xin-Ping Li, Wei Jing, Jian-Jun Sun, Zhong-Yan Liu, Jing-Tao Zhang, Wei Sun, Wei Zhu, Yue-Zu Fan. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1521-5
|
| 9 |
Ming-Che Chang, Jin-Yi Wu, Hui-Fen Liao, Yu-Jen Chen, Cheng-Deng Kuo. N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production. Anti-Cancer Drugs 2015; 26(10): 1034 doi: 10.1097/CAD.0000000000000284
|
| 10 |
Yu-Jen Chen, Cheng-Deng Kuo, Yin-Meng Tsai, Chih-Chia Yu, Guang-Sheng Wang, Hui-Fen Liao. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anti-Cancer Drugs 2008; 19(1): 55 doi: 10.1097/CAD.0b013e3282f18826
|
| 11 |
Xiaofen Xu, Yanggong Li, Feihu Wang, Li Lv, Jieying Liu, Mingna Li, Aijie Guo, Jinjun Jiang, Yuanyuan Shen, Shengrong Guo. Synthesis, in vitro and in vivo evaluation of new norcantharidin-conjugated hydroxypropyltrimethyl ammonium chloride chitosan derivatives as polymer therapeutics. International Journal of Pharmaceutics 2013; 453(2): 610 doi: 10.1016/j.ijpharm.2013.05.052
|
| 12 |
Pei-Yu Yang, Ming-Feng Chen, Chi-Hong Tsai, Dan-Ning Hu, Fang-Rong Chang, Yang-Chang Wu. Involvement of caspase and MAPK activities in norcantharidin-induced colorectal cancer cell apoptosis. Toxicology in Vitro 2010; 24(3): 766 doi: 10.1016/j.tiv.2009.12.025
|
| 13 |
Hui-Fen Liao, Yu-Jen Chen, Chin-Hung Chou, Fang-Wei Wang, Cheng-Deng Kuo. Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production. Toxicology in Vitro 2011; 25(1): 206 doi: 10.1016/j.tiv.2010.11.001
|
| 14 |
Ming-Che Chang, Jin-Yi Wu, Hui-Fen Liao, Yu-Jen Chen, Cheng-Deng Kuo. Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast. Medicine 2016; 95(31): e4467 doi: 10.1097/MD.0000000000004467
|
| 15 |
Cheng Peng, Xiangqun Liu, Enyu Liu, Kesen Xu, Weibo Niu, Rong Chen, Jiayong Wang, Zhaoyang Zhang, Pengfei Lin, Jian Wang, Michael Agrez, Jun Niu. Norcantharidin induces HT‐29 colon cancer cell apoptosis through the αvβ6–extracellular signal‐related kinase signaling pathway. Cancer Science 2009; 100(12): 2302 doi: 10.1111/j.1349-7006.2009.01320.x
|
| 16 |
Long Zhang, Qing Ji, Xuan Liu, Xingzhu Chen, Zhaohua Chen, Yanyan Qiu, Jian Sun, Jianfeng Cai, Huirong Zhu, Qi Li. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways. Cancer Science 2013; 104(5): 604 doi: 10.1111/cas.12120
|
| 17 |
Xinglu Chen, Xiangsheng Cai, Dianpeng Zheng, Xiuya Huang, Ying Chen, Tanggang Deng, Lijun Mo, Hongwei Li, Jinlong Li, Sansan Chen. Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro. Anti-Cancer Drugs 2022; 33(1): e94 doi: 10.1097/CAD.0000000000001147
|
| 18 |
Mu-Su Pan, Jin Cao, Yue-Zu Fan. Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities. Chinese Medicine 2020; 15(1) doi: 10.1186/s13020-020-00338-6
|
| 19 |
Xiaofen Xu, Yanggong Li, Yuanyuan Shen, Shengrong Guo. Synthesis and in vitro cellular evaluation of novel anti-tumor norcantharidin-conjugated chitosan derivatives. International Journal of Biological Macromolecules 2013; 62: 418 doi: 10.1016/j.ijbiomac.2013.09.053
|
| 20 |
Xin-Zhong Chang, Zhan-Min Wang, Jin-Ming Yu, Fu-Guo Tian, Wei Jin, Yi Zhang, Jie Yu, Lian-Fang Li, Xiao-Feng Liu, Zhi-Wei Li, Zhi-Min Shao. Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides. Clinical & Experimental Metastasis 2007; 24(1): 25 doi: 10.1007/s10585-006-9053-7
|
| 21 |
Hui Wang, Wei Sun, Wen-Zhong Zhang, Chun-Yan Ge, Jing-Tao Zhang, Zhong-Yan Liu, Yue-Zu Fan, Jun Li. Inhibition of Tumor Vasculogenic Mimicry and Prolongation of Host Survival in Highly Aggressive Gallbladder Cancers by Norcantharidin via Blocking the Ephrin Type a Receptor 2/Focal Adhesion Kinase/Paxillin Signaling Pathway. PLoS ONE 2014; 9(5): e96982 doi: 10.1371/journal.pone.0096982
|